People

Mahnsoon Hwang

Mahnsoon Hwang (황만순) is published in Korea Investment Partners’ current Management Executives directory as CEO. Mahnsoon earned his bachelor's and master's degrees in Pharmacy from Seoul National University, then began his career as an R&D researcher at Yuhan Corporation. He went on to serve as Vice President at both Yuhan Corporation and ChemOn, building deep expertise in biotech and healthcare through hands-on experience ranging from new pipeline development to clinical-stage trials. Drawing on this industry background, he recognized greater potential in the role of a venture capitalist — supporting promising biotech companies with capital and strategy to help them grow. This realization led him to Korea Bio Technology Investment, and subsequently to Korea Investment Partners, which he joined in 2009. A veteran investor with a track record spanning investments in promising biotech companies both in Korea and abroad, he has experience seeing portfolio companies through to IPOs and M&A exits not only domestically but internationally as well, and currently manages a cumulative fund of over KRW 700 billion. As both a VC investor and a leader in Korea's biotech industry, he is active across a wide range of initiatives — achievements for which he received a Presidential Citation in 2025. Published education: M.S., Pharmacy, Seoul National University. The primary profile’s career/background list names Yuhan Corporation, Korea BioTechnology Investment, CHEMON, Affiliated Professor for Ewha Womans Univ. Medical Center(Clinical Trials), Chairman of New Industry Organization for Investment, Member of K ARPA-H; undated entries are not independently verified concurrent appointments. Published areas: Bio, Healthcare, Pharma. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.